Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:2016:1279042.
doi: 10.1155/2016/1279042. Epub 2016 Dec 5.

Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy

Mariana Babayeva  1 , Haregewein Assefa  1 , Paramita Basu  1 , Sanjeda Chumki  1 , Zvi Loewy  1
Affiliations
Review

Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy

Mariana Babayeva et al. Parkinsons Dis. 2016.

Abstract

Parkinson's disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States. Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons. The current treatment is symptomatic and mainly involves replacement of dopamine deficiency. This therapy improves only motor symptoms of Parkinson's disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet need for more comprehensive approach in the management of PD. Cannabis and related compounds have created significant research interest as a promising therapy in neurodegenerative and movement disorders. In this review we examine the potential benefits of medical marijuana and related compounds in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease. The potential for cannabis to enhance the quality of life of Parkinson's patients is explored.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

    1. Borgelt L. M., Franson K. L., Nussbaum A. M., Wang G. S. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195–209. doi: 10.1002/phar.1187. - DOI - PubMed
    1. ElSohly M. A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences. 2005;78(5):539–548. doi: 10.1016/j.lfs.2005.09.011. - DOI - PubMed
    1. Russo E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x. - DOI - PMC - PubMed
    1. Rahn E. J., Hohmann A. G. Cannabinoids as Pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–737. doi: 10.1016/j.nurt.2009.08.002. - DOI - PMC - PubMed
    1. Zuardi A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria. 2008;30(3):271–280. doi: 10.1590/s1516-44462008000300015. - DOI - PubMed